Profound Medical Corp. (PROF) Stock Forecast
PROF analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $11.14 average of analyst targets
- Upside to target
- +85.4% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.19
- 52-week range
- $5.06 – $8.65
PROF analyst ratings
5 analystsNumber of analysts at each rating.
PROF price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PROF earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.22 | −$0.16 | −$0.26 | +25.0% | 4 |
| Current fiscal year (2026) | −$0.84 | −$0.86 | −$0.82 | −$1.41 | +40.6% | 4 |
| Next fiscal year (2027) | −$0.59 | −$0.77 | −$0.07 | −$0.84 | +29.8% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PROF revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $14.0M | $14.0M | $14.0M | +88.4% | 2 |
| Current fiscal year (2026) | $37.4M | $35.0M | $40.5M | +69.3% | 5 |
| Next fiscal year (2027) | $60.0M | $53.5M | $65.4M | +60.7% | 5 |
PROF EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PROF revenue: reported and forecast
PROF EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.23 | −$0.23 | −$0.23 | −$0.20 | −19.6% | 2 up · 0 down |
| Current fiscal year (2026) | −$0.84 | −$0.87 | −$0.86 | −$0.86 | −$0.84 | −0.8% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.75 | −$0.59 | −$0.59 | −$0.59 | −$0.59 | −21.8% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PROF earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PROF beat in 8 of 12.
What analysts expect from PROF
5 analysts cover Profound Medical; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.14, 85.4% above the latest close of $6.01. Analysts expect earnings of −$0.84 per share for 2026, +40.6% from a year earlier. For 2027 the average estimate is −$0.59 per share on revenue of $60.0 million. Profound Medical beat the EPS estimate in 8 of the last 12 quarters.
Related: PROF income statement, PROF key metrics, PROF chart. See the PROF stock overview for the latest quote and news.
PROF forecast FAQ
What is Profound Medical's price target?
The average analyst price target for Profound Medical is $11.14, 85.4% above the latest close of $6.01.
Is Profound Medical a buy, hold or sell?
Of 5 analysts covering Profound Medical, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Profound Medical's EPS forecast?
Analysts forecast −$0.84 per share for 2026 (range −$0.86 to −$0.82); for 2027 the estimate is −$0.59.
What is Profound Medical's revenue forecast?
The average revenue estimate for 2026 is $37.4 million, growth of 69.3%; for 2027 it is $60.0 million.
When does Profound Medical report earnings?
Profound Medical is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.19.
Does Profound Medical usually beat earnings estimates?
Profound Medical reported EPS at or above the analyst estimate in 8 of the last 12 quarters.